Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

$24.99

DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Two-Component Disaggregation of ROE

Vertex Pharmaceuticals Inc., decomposition of ROE (quarterly data)

Microsoft Excel
ROE = ROA × Financial Leverage
Dec 31, 2025 = ×
Sep 30, 2025 = ×
Jun 30, 2025 = ×
Mar 31, 2025 = ×
Dec 31, 2024 = ×
Sep 30, 2024 = ×
Jun 30, 2024 = ×
Mar 31, 2024 = ×
Dec 31, 2023 = ×
Sep 30, 2023 = ×
Jun 30, 2023 = ×
Mar 31, 2023 = ×
Dec 31, 2022 = ×
Sep 30, 2022 = ×
Jun 30, 2022 = ×
Mar 31, 2022 = ×

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The financial performance, as indicated by Return on Equity (ROE) and its components, exhibits notable fluctuations over the observed period. Initially, a generally positive trend is apparent, followed by a significant downturn and subsequent recovery. The analysis focuses on the interplay between Return on Assets (ROA) and Financial Leverage in driving these ROE changes.

Return on Assets (ROA)
ROA demonstrates a generally stable performance in the earlier part of the period, fluctuating between approximately 17% and 20.5% from March 2022 to December 2022. A gradual decline is then observed through September 2023, reaching a low of 15.97%. A sharp negative shift occurs in the subsequent quarters, with ROA falling to -2.43% by June 2024. This negative trend continues into early 2025, bottoming out at -4.32% in March 2025, before a substantial recovery begins, culminating in 15.42% by December 2025.
Financial Leverage
Financial Leverage remains relatively consistent between 1.28 and 1.32 for much of the period, from March 2022 through September 2023. A slight increase is noted in the latter half of 2024, peaking at 1.42 in June 2024, before decreasing to 1.37 by December 2024. The leverage ratio stabilizes around 1.40 in the first half of 2025, then decreases slightly to 1.37 by the end of 2025.
Return on Equity (ROE)
ROE mirrors the trend observed in ROA for the initial period, starting at 22.47% in March 2022 and peaking at 26.77% in June 2022, before declining to 20.59% by December 2022. The decline continues through September 2023, reaching 21.01%. A dramatic decrease is then evident, with ROE becoming negative at -3.32% by June 2024. This negative value persists through December 2024, reaching -5.99% in March 2025. A strong recovery is then observed, with ROE returning to positive territory and reaching 21.18% by December 2025.
ROE Disaggregation
The significant decline in ROE during 2024 and early 2025 is primarily attributable to the substantial decrease in ROA. While Financial Leverage increased slightly during this period, its impact was insufficient to offset the negative ROA. The subsequent recovery in ROE from mid-2025 is driven by the rebound in ROA, with Financial Leverage remaining relatively stable. The initial ROE values are largely a product of moderate ROA combined with consistent financial leverage. The period from March 2022 to December 2022 shows a relatively stable ROE, driven by both ROA and leverage remaining within a narrow range.

In conclusion, the observed fluctuations in ROE are strongly correlated with changes in ROA, with Financial Leverage playing a secondary, stabilizing role. The period of negative ROE highlights the sensitivity of overall profitability to asset utilization and efficiency.


Three-Component Disaggregation of ROE

Vertex Pharmaceuticals Inc., decomposition of ROE (quarterly data)

Microsoft Excel
ROE = Net Profit Margin × Asset Turnover × Financial Leverage
Dec 31, 2025 = × ×
Sep 30, 2025 = × ×
Jun 30, 2025 = × ×
Mar 31, 2025 = × ×
Dec 31, 2024 = × ×
Sep 30, 2024 = × ×
Jun 30, 2024 = × ×
Mar 31, 2024 = × ×
Dec 31, 2023 = × ×
Sep 30, 2023 = × ×
Jun 30, 2023 = × ×
Mar 31, 2023 = × ×
Dec 31, 2022 = × ×
Sep 30, 2022 = × ×
Jun 30, 2022 = × ×
Mar 31, 2022 = × ×

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The three-component DuPont analysis reveals fluctuating performance over the observed period. Return on Equity (ROE) initially demonstrated growth, peaking in the first quarter of 2022, before experiencing a decline through 2023. A significant disruption is observed in the first half of 2024, followed by a recovery towards the end of 2025, though not reaching prior levels. This ROE trajectory is influenced by changes in Net Profit Margin, Asset Turnover, and Financial Leverage.

Net Profit Margin
The Net Profit Margin exhibited an upward trend from the first quarter of 2022 to the fourth quarter of 2022, reaching a high of 38.26%. It then stabilized in the first half of 2023 before experiencing a dramatic decrease in the first two quarters of 2024, resulting in negative values. A substantial recovery is then seen in the latter half of 2024 and throughout 2025, returning to levels comparable to those observed in 2022 and 2023. This volatility significantly impacts overall ROE.
Asset Turnover
Asset Turnover generally decreased from 0.56 in the first quarter of 2022 to 0.43 in the fourth quarter of 2023, indicating a declining efficiency in generating sales from assets. A slight increase is observed in the first quarter of 2024, but it remains below the levels seen in 2022. The ratio stabilizes around 0.47-0.49 in the latter part of the period, suggesting limited improvement in asset utilization. This consistent decline contributes to the overall downward pressure on ROE.
Financial Leverage
Financial Leverage remained relatively stable between 1.28 and 1.32 for most of the period, indicating a consistent use of debt financing. A slight increase is observed in the first two quarters of 2024, peaking at 1.42, before decreasing to 1.37 by the end of 2025. While leverage contributes to magnifying ROE, its impact is overshadowed by the fluctuations in Net Profit Margin and the decline in Asset Turnover.

The substantial decline in ROE during the first half of 2024 is primarily attributable to the negative Net Profit Margin. While increased financial leverage partially offset this decline, it was insufficient to maintain positive ROE. The subsequent recovery in ROE towards the end of the period is largely driven by the restoration of profitability, as evidenced by the rebound in Net Profit Margin. The relatively stable, and slightly declining, Asset Turnover suggests that improvements in operational efficiency are not a primary driver of the observed changes in ROE.


Five-Component Disaggregation of ROE

Vertex Pharmaceuticals Inc., decomposition of ROE (quarterly data)

Microsoft Excel
ROE = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Financial Leverage
Dec 31, 2025 = × × × ×
Sep 30, 2025 = × × × ×
Jun 30, 2025 = × × × ×
Mar 31, 2025 = × × × ×
Dec 31, 2024 = × × × ×
Sep 30, 2024 = × × × ×
Jun 30, 2024 = × × × ×
Mar 31, 2024 = × × × ×
Dec 31, 2023 = × × × ×
Sep 30, 2023 = × × × ×
Jun 30, 2023 = × × × ×
Mar 31, 2023 = × × × ×
Dec 31, 2022 = × × × ×
Sep 30, 2022 = × × × ×
Jun 30, 2022 = × × × ×
Mar 31, 2022 = × × × ×

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The five-component DuPont analysis reveals fluctuating performance metrics over the observed period. Initially, from March 2022 through September 2022, Return on Equity (ROE) demonstrated a slight downward trend, followed by relative stability through December 2023. A significant disruption occurred in the first half of 2024, with ROE turning negative, before a partial recovery towards the end of the period. The individual components contributing to ROE exhibit varying patterns, offering insights into the drivers of these changes.

Tax Burden
The tax burden remained relatively stable around 0.81-0.86 for most of the period, indicating a consistent effective tax rate. However, a substantial negative tax burden is observed in June and September 2024, and December 2024, which significantly impacted ROE during those quarters. This warrants further investigation to understand the underlying cause, potentially related to tax benefits or accounting adjustments.
Interest Burden
The interest burden remained consistently high, near 0.98-1.00, throughout most of the period, suggesting a substantial portion of earnings is allocated to interest expense. A decrease to 0.84-0.89 is observed in the first half of 2024, coinciding with the negative ROE, but it recovers to 1.00 by September 2025. This suggests a potential relationship between interest expense management and overall profitability.
EBIT Margin
The EBIT margin exhibited a strong performance in the first half of the observed period, peaking at 47.81% in June 2022, before gradually declining to around 44-45% through September 2023. A dramatic decrease is then observed in the first half of 2024, with the margin falling to 2.48% and 2.80%, respectively. This decline is a primary driver of the negative ROE experienced during that time. The margin partially recovers to 38.06% and 38.80% in June and September 2025, but remains below the levels seen earlier in the period.
Asset Turnover
Asset turnover showed a gradual decline from 0.56 in March 2022 to 0.43 in December 2023, indicating decreasing efficiency in utilizing assets to generate revenue. A slight increase to 0.51 and 0.48 is observed in the first half of 2024, but it remains relatively stable around 0.47-0.49 through the end of the period. This suggests that asset utilization has not significantly improved despite the fluctuations in other components.
Financial Leverage
Financial leverage remained relatively stable between 1.28 and 1.36 for most of the period, indicating a consistent level of debt financing. A slight increase is observed in the first half of 2024, peaking at 1.42 in June 2024, which could have amplified the negative impact of the declining EBIT margin on ROE. Leverage then decreases slightly to 1.37 by December 2025.

In summary, the observed fluctuations in ROE are primarily driven by changes in the EBIT margin, with the negative tax burden in mid-2024 exacerbating the decline. While financial leverage remained relatively consistent, its impact was amplified during periods of low profitability. Asset turnover showed a gradual decline, suggesting potential inefficiencies in asset utilization. The period from January 2024 through December 2024 represents a period of significant underperformance, requiring further investigation to understand the underlying causes and implement corrective measures.


Two-Component Disaggregation of ROA

Vertex Pharmaceuticals Inc., decomposition of ROA (quarterly data)

Microsoft Excel
ROA = Net Profit Margin × Asset Turnover
Dec 31, 2025 = ×
Sep 30, 2025 = ×
Jun 30, 2025 = ×
Mar 31, 2025 = ×
Dec 31, 2024 = ×
Sep 30, 2024 = ×
Jun 30, 2024 = ×
Mar 31, 2024 = ×
Dec 31, 2023 = ×
Sep 30, 2023 = ×
Jun 30, 2023 = ×
Mar 31, 2023 = ×
Dec 31, 2022 = ×
Sep 30, 2022 = ×
Jun 30, 2022 = ×
Mar 31, 2022 = ×

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The financial performance, as indicated by the two-component disaggregation of Return on Assets (ROA), demonstrates a period of initial strength followed by a notable shift in profitability and efficiency. A general trend of declining asset turnover is observed alongside fluctuating net profit margins, ultimately impacting ROA.

Net Profit Margin
The Net Profit Margin exhibited an increasing trend from March 31, 2022, peaking at 38.26% in June 2022, before stabilizing around the 35-37% range through September 2023. A significant decline is then apparent, with negative values recorded from March 31, 2024, through December 31, 2024. A recovery begins in March 31, 2025, with margins returning to the 31-33% range by the end of the observed period. This volatility suggests potential shifts in cost structures, pricing strategies, or product mix.
Asset Turnover
Asset Turnover consistently decreased from 0.56 in March 31, 2022, to 0.43 by December 31, 2023, indicating a diminishing ability to generate sales from its asset base. A slight increase is observed in June 30, 2024 (0.51), but the ratio quickly reverts to the 0.47-0.49 range and remains relatively stable through December 31, 2025. This sustained decline suggests potential inefficiencies in asset utilization or an increase in assets relative to sales.
Return on Assets (ROA)
ROA mirrored the combined effect of the Net Profit Margin and Asset Turnover trends. It peaked at 20.50% in June 30, 2022, and generally declined to 15.92% by December 31, 2023. The negative Net Profit Margin values in 2024 resulted in a negative ROA, reaching a low of -4.32% in March 31, 2025. A subsequent recovery in Net Profit Margin contributed to an increase in ROA, reaching 15.42% by December 31, 2025, though still below the levels observed in 2022. The correlation between ROA and the Net Profit Margin is particularly strong, highlighting the margin’s significant influence on overall asset profitability.

The period under review demonstrates a clear shift in financial performance. While initial periods showed robust profitability and efficient asset utilization, later periods were characterized by declining efficiency and a substantial, albeit temporary, decline in profitability. The recovery observed towards the end of the period suggests potential corrective actions or favorable market conditions, but sustained monitoring is warranted.


Four-Component Disaggregation of ROA

Vertex Pharmaceuticals Inc., decomposition of ROA (quarterly data)

Microsoft Excel
ROA = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover
Dec 31, 2025 = × × ×
Sep 30, 2025 = × × ×
Jun 30, 2025 = × × ×
Mar 31, 2025 = × × ×
Dec 31, 2024 = × × ×
Sep 30, 2024 = × × ×
Jun 30, 2024 = × × ×
Mar 31, 2024 = × × ×
Dec 31, 2023 = × × ×
Sep 30, 2023 = × × ×
Jun 30, 2023 = × × ×
Mar 31, 2023 = × × ×
Dec 31, 2022 = × × ×
Sep 30, 2022 = × × ×
Jun 30, 2022 = × × ×
Mar 31, 2022 = × × ×

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The four-component disaggregation of Return on Assets (ROA) reveals notable shifts in profitability, efficiency, and financial leverage over the observed period. A generally declining trend in ROA is apparent, though punctuated by periods of relative stability and, more recently, significant volatility. The interplay between EBIT Margin, Asset Turnover, Interest Burden, and Tax Burden explains these fluctuations.

EBIT Margin
The EBIT Margin demonstrates a strong performance through the end of 2022, fluctuating between 36.80% and 48.01%. However, a substantial decline is observed beginning in March 2023, reaching a low of -2.50% in March 2024. A recovery is then seen in the subsequent periods, returning to approximately 38% by September 2025. This volatility significantly impacts overall ROA.
Asset Turnover
Asset Turnover exhibits a consistent, albeit gradual, downward trend from 0.56 in March 2022 to 0.47 in September 2025. While the declines are relatively small each quarter, the cumulative effect contributes to the overall reduction in ROA. A slight increase is observed in June 2024, but this does not reverse the longer-term trend. The ratio stabilizes around 0.47-0.49 in the latter part of the period.
Interest Burden
The Interest Burden remains consistently high, near 0.99, throughout most of the period until June 2024. A decrease to 0.84 in June 2024, followed by increases to 0.87, 0.89, and then a return to 1.00 by September 2025, suggests a change in the company’s debt management or interest expense profile. This fluctuation has a minor impact on ROA, given its consistently high value.
Tax Burden
The Tax Burden generally remains stable around 0.81-0.86 until June 2024, when it experiences significant negative values (-2.28 and -1.85). These negative values in June and September 2024, and again in December 2024, likely indicate the realization of tax benefits or changes in tax liabilities. The Tax Burden recovers to 0.83 in March 2025 and 0.85 in December 2025, suggesting a return to more typical tax obligations. This ratio’s volatility contributes to the fluctuations in ROA, particularly in 2024.

The decline in ROA from 2022 to 2024 is primarily driven by the substantial decrease in the EBIT Margin, compounded by the gradual reduction in Asset Turnover. The negative Tax Burden values in 2024 introduce significant volatility. The stabilization and slight recovery in the EBIT Margin towards the end of the period, coupled with a relatively stable Asset Turnover, suggest a potential for ROA stabilization, though the impact of the Interest Burden and Tax Burden will continue to be important factors.


Disaggregation of Net Profit Margin

Vertex Pharmaceuticals Inc., decomposition of net profit margin ratio (quarterly data)

Microsoft Excel
Net Profit Margin = Tax Burden × Interest Burden × EBIT Margin
Dec 31, 2025 = × ×
Sep 30, 2025 = × ×
Jun 30, 2025 = × ×
Mar 31, 2025 = × ×
Dec 31, 2024 = × ×
Sep 30, 2024 = × ×
Jun 30, 2024 = × ×
Mar 31, 2024 = × ×
Dec 31, 2023 = × ×
Sep 30, 2023 = × ×
Jun 30, 2023 = × ×
Mar 31, 2023 = × ×
Dec 31, 2022 = × ×
Sep 30, 2022 = × ×
Jun 30, 2022 = × ×
Mar 31, 2022 = × ×

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The disaggregation of net profit margin reveals notable fluctuations across the observed period. Significant shifts are evident in the relationship between EBIT margin, tax burden, and interest burden, impacting overall profitability. A period of relative stability from March 2022 through December 2022 is followed by a substantial disruption in the subsequent quarters.

EBIT Margin
The EBIT margin demonstrates a generally strong performance from March 2022 to December 2022, fluctuating between 36.80% and 48.01%. However, a dramatic decline is observed starting in March 2023, reaching a low of -2.50% in March 2024. A partial recovery is then seen, with the margin increasing to 38.80% by December 2025. This suggests a significant operational challenge during the period of decline, followed by some improvement.
Tax Burden
The tax burden remains relatively consistent around 0.81 to 0.86 from March 2022 to September 2023. A notable deviation occurs in March 2024 (-2.28) and continues through December 2024 (-2.16), indicating a potential impact from tax-related events or accounting adjustments. The tax burden returns to a more typical range of 0.83 to 0.85 in the final two quarters of the observed period.
Interest Burden
The interest burden consistently remains high, near 0.99, from March 2022 to September 2023, suggesting a substantial level of debt financing. A decrease is observed starting in March 2024, reaching 0.89 by December 2024, potentially indicating debt reduction or refinancing. The interest burden then stabilizes at 1.00 for the final two quarters, suggesting a return to higher financing costs.
Net Profit Margin
The net profit margin mirrors the trends observed in the EBIT margin, exhibiting a strong performance between 30.84% and 38.26% from March 2022 to December 2022. A significant decline begins in March 2023, with the margin falling to negative values (-4.74% to -8.91%) between March 2024 and December 2024. A recovery is then evident, with the margin reaching 32.94% by December 2025, though it remains below the levels seen in the earlier period. The negative values suggest a period where expenses, including taxes and interest, exceeded revenues.

The substantial decline in net profit margin, coinciding with the drop in EBIT margin and fluctuations in tax and interest burdens, warrants further investigation. The recovery observed in the latter part of the period suggests corrective actions may be taking effect, but sustained monitoring is necessary to confirm a return to previous profitability levels.